IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 221 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $21,026,708 | -62.5% | 2,621,784 | -30.7% | 0.00% | -60.0% |
Q1 2024 | $56,057,583 | +87.3% | 3,782,563 | +2.7% | 0.01% | +66.7% |
Q4 2023 | $29,931,082 | +74.8% | 3,681,560 | -2.2% | 0.01% | +50.0% |
Q3 2023 | $17,124,553 | -31.2% | 3,763,638 | +6.5% | 0.00% | -20.0% |
Q2 2023 | $24,888,280 | +3.6% | 3,535,267 | -10.1% | 0.01% | -16.7% |
Q1 2023 | $24,030,532 | +3.2% | 3,932,984 | +8.0% | 0.01% | 0.0% |
Q4 2022 | $23,279,185 | +81034.8% | 3,643,065 | +21.6% | 0.01% | -14.3% |
Q3 2022 | $28,692 | +33.1% | 2,994,979 | +53.4% | 0.01% | +40.0% |
Q2 2022 | $21,554 | -99.8% | 1,952,346 | +225.7% | 0.01% | +150.0% |
Q1 2022 | $9,979,000 | -65.0% | 599,371 | -59.9% | 0.00% | -60.0% |
Q4 2021 | $28,525,000 | -7.8% | 1,494,204 | +19.1% | 0.01% | -28.6% |
Q3 2021 | $30,951,000 | -30.9% | 1,255,100 | -27.1% | 0.01% | -30.0% |
Q2 2021 | $44,822,000 | -26.2% | 1,722,578 | -10.2% | 0.01% | -33.3% |
Q1 2021 | $60,709,000 | +75.4% | 1,917,509 | +157.1% | 0.02% | +66.7% |
Q4 2020 | $34,604,000 | +28.3% | 745,770 | -9.0% | 0.01% | +12.5% |
Q3 2020 | $26,967,000 | -31.4% | 819,151 | -42.8% | 0.01% | -33.3% |
Q2 2020 | $39,290,000 | +16.3% | 1,431,325 | +26.8% | 0.01% | 0.0% |
Q1 2020 | $33,785,000 | -0.8% | 1,128,608 | -8.2% | 0.01% | +50.0% |
Q4 2019 | $34,044,000 | +78.5% | 1,229,954 | +17.4% | 0.01% | +33.3% |
Q3 2019 | $19,070,000 | +35.6% | 1,047,792 | +82.7% | 0.01% | +50.0% |
Q2 2019 | $14,060,000 | +238.1% | 573,378 | +31.1% | 0.00% | +300.0% |
Q1 2019 | $4,158,000 | -32.2% | 437,263 | -36.9% | 0.00% | -50.0% |
Q4 2018 | $6,136,000 | +183.3% | 693,301 | +260.1% | 0.00% | +100.0% |
Q3 2018 | $2,166,000 | +99.1% | 192,536 | +126.4% | 0.00% | – |
Q2 2018 | $1,088,000 | -32.1% | 85,037 | -10.3% | 0.00% | – |
Q1 2018 | $1,602,000 | +215.4% | 94,793 | +49.5% | 0.00% | – |
Q4 2017 | $508,000 | -70.6% | 63,414 | -71.5% | 0.00% | – |
Q3 2017 | $1,727,000 | +9.7% | 222,784 | +4.0% | 0.00% | – |
Q2 2017 | $1,575,000 | – | 214,211 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 3,019,201 | $26,720,000 | 20.38% |
Broadfin Capital, LLC | 5,951,153 | $52,668,000 | 6.92% |
GREAT POINT PARTNERS LLC | 5,567,348 | $49,271,000 | 6.23% |
Avoro Capital Advisors LLC | 10,261,039 | $90,810,000 | 5.43% |
FRAZIER MANAGEMENT LLC | 2,188,331 | $19,367,000 | 5.00% |
Prosight Management, LP | 1,062,500 | $9,403,000 | 4.85% |
Perceptive Advisors | 12,241,111 | $108,333,000 | 4.12% |
Ghost Tree Capital, LLC | 1,000,000 | $8,850,000 | 3.21% |
QVT Financial LP | 1,021,361 | $8,696,000 | 2.84% |
Vivo Capital, LLC | 1,600,000 | $14,160,000 | 1.81% |